Treatment for AMD: the Autorité fines 3 laboratories for abusive practices


The Autorité de la concurrence has imposed fines worth a total of €444 million on three pharmaceutical companies, Novartis, Roche and Genentech, for abusive practices designed to sustain the sales of Lucentis for AMD treatment to the detriment of Avastin (a competitive medicinal product that is 30 times cheaper).

Sanction dans le secteur de l'ophtalmologie

Print the page